• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nanovibronix Inc (NQ: NAOV )

    0.5080 UNCHANGED
    Streaming Delayed Price Updated: 3:07 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Nanovibronix Inc

    < Previous 1 2 3 Next >
    NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Signs Letter of Intent with Potential New Distributor
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Issues Letter to Stockholders
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs’ FSS Contract Award
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Issues Letter to Stockholders
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Featured in Your Bladder Health Magazine
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Regains Nasdaq Compliance
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Issues Letter to Shareholders
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
    From NanoVibronix, Inc.
    Via Business Wire
    BioMedNewsBreaks – IBN’s BioMedWire Highlights NanoVibronix Inc.’s (NASDAQ: NAOV) $5M Private Placement
    Via Investor Brand Network
    NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Inc. (NASDAQ: NAOV) is One of Wednesday Morning’s Most Active Stocks
    Via Investor Brand Network
    NanoVibronix Cites Positive Results from Independent Testing of UroShield
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Responds to CMS’ Determination for PainShield
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Issues Letter to Shareholders
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Issues Letter to Shareholders
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra
    From NanoVibronix, Inc.
    Via Business Wire
    NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury
    From NanoVibronix, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.